Les Echos – SME-Regions / Innovators
By Emmanuel Guimard – July 4, 2025

The nuclear energy specialist will invest €20 to €30 million in a first production capacity for astatine-211, a promising radionuclide in the fight against cancer. This facility is expected to be operational in 2027 or 2028.

Framatome is stepping up its presence in nuclear medicine. The French group announces the installation of an astatine-211 production unit in Saint-Herblain (Loire-Atlantique), near Nantes. Framatome Healthcare is partnering with Belgian company IBA to design the cyclotron required for manufacturing this radioisotope.

Reference

Source: Les Echos, SME-Regions / Innovators

Author: Emmanuel Guimard

Date: July 4, 2025

Link to original article: www.lesechos.fr